Skip to content

Condition

Cholangiocarcinoma (Bile Duct Cancer)

Cancer of the bile ducts, including FGFR2-altered unresectable or metastatic disease.
All latest →
FDA ApprovedUnited States

New Oral Pill Option for Previously Treated Bile Duct Cancer

Lyrfigtu (lirafugratinib) — oral FGFR2 inhibitor for previously treated FGFR2-altered cholangiocarcinoma

FDA approved 23 Sep 2026 for adults with previously treated unresectable/metastatic CCA harboring an FGFR2 fusion or other rearrangement

This is for adults with previously treated unresectable, locally advanced, or metastatic bile duct cancer…